Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei

Carina M. Hall, Nawarat Somprasong, Johannah P. Hagen, Roxanne Nottingham, Jason W. Sahl, Jessica R. Webb, Mark Mayo, Bart J. Currie, Yuwana Podin, David M. Wagner, Paul Keim, Herbert P. Schweizer

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Cefiderocol is a siderophore cephalosporin designed mainly for treatment of infections caused by b-lactam and multidrug-resistant Gram-negative bacteria. Burkholderia pseudomallei clinical isolates are usually highly cefiderocol susceptible, with in vitro resistance found in a few isolates. Resistance in clinical B. pseudomallei isolates from Australia is caused by a hitherto uncharacterized mechanism. We show that, like in other Gram-negatives, the PiuA outer membrane receptor plays a major role in cefiderocol nonsusceptibility in isolates from Malaysia.

Original languageEnglish (US)
JournalAntimicrobial Agents and Chemotherapy
Issue number6
StatePublished - Jun 2023


  • Burkholderia pseudomallei
  • cefiderocol
  • resistance

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases


Dive into the research topics of 'Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei'. Together they form a unique fingerprint.

Cite this